Specific methylation in cancer cells has been highlighted as a biomarker owing to its high sensitivity to aberrant methylation in cancer.24 This being said, our study potentially provides a theoretical basis for which lncRNA TNRC6C‐AS1 may be premised upon as a therapeutic target for TC treatment. Here, TNRC6C is linked to cancer.